Have to agree with views above that the way AXE presents is lacking something.
"Strong industry partnerships and links with leading research institutes" in the last presentation slides says absolutely nothing. This was when the Hylid partnership was already announced and a few weeks later one more partnership with Paragraf was announced. It didn't bring out the 3 pronged development effort for the biochip. The third being AXE's own success in Sydney integrating the biochip connects with readout circuitry.
There is a lot going on with AXE but it is now at a phase with the biochip when it can do a better job presenting the R&D.
To me AXE is also becoming it's own nanotechnology R&D hub rather than farming it out to an Infineon or an Imec. So maybe a name change to Archer nanotechnology will give everyone a much better understanding of what AXE does. It's R&D has not 1 but 3 products so far with hints of yet not looked into stuff. The government could also step in and support AXE a lot better if it saw the nanotech expertise concentration at AXE. Also the Board could do with some nanotechnology talent.
AXE Price at posting:
27.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)